Anesthesia Complication
Conditions
Keywords
dexmedetomidine, coughing during anesthetic emergence, thyroid surgery
Brief summary
Maintenance of a remifentanil infusion during anesthetic emergence has been reported to decrease the incidence of coughing and thereby help to ensure a smooth emergence. It may, however, cause respiratory depression and possibly delay emergence. The purpose of this study was to investigate the effect of different dose of dexmedetomidine infusion on cough suppression during emergence from general anesthesia in patients undergoing thyroid surgery. American Society of Anesthesiologists physical status I-II adults undergoing elective thyroidectomy under general anesthesia are recruited and randomly allocated to receive dexmedetomidine iv infusion of 0.2μg·kg-1·h-1 (Group D1, n = 100), 0.5μg·kg-1·h-1 (Group D2, n = 100), 0.7μg·kg-1·h-1 (Group D3, n = 100) or saline (Group C, n = 100). Primary outcome is the incidence of coughing during emergence. Second outcomes include severity of coughing, which is assessed using a four-point scale; Ramsay score, Bruggrmann comfort scale score, VAS pain score are recorded. The respiratory rate (RR), heart rate (HR), and mean arterial pressure are also recorded.
Interventions
DRUGDexmedetomidine Hydrochloride
Dexmedetomidine Hydrochloride 0.2 μg·kg-1·h-will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
DRUGNormal Saline
Normal saline 0.5 mL·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
Sponsors
Min Su
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. 30Kg/m2 ≥ BMI \> 18Kg/m2; 2. undergoing general anesthesia; 3. ASA physical status I and II 4. undergoing elective thyroid surgery.
Exclusion criteria
1. hyperthyroidism; 2. preoperative bradycardia; 3. liver function impairment; 4. renal function impairment; 5. heart function failure; 6. history of asthma or COPD; 7. history of diabetes; 8. cognition function impairment; 9. pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of coughing during anesthetic emergence | within 10 minutes after endotracheal extubation | incidence of coughing within 10 minutes after extubation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ramsay score during anesthetic emergence | within 30 minutes after endotracheal extubation | Ramsay score 1min, 5min, 10min, and 30min after extubation |
| Bruggrmann comfort scale score | within 24 hrs after endotracheal extubation | Bruggrmann comfort scale score 30min and 24 hrs after extubation |
| VAS pain score | within 48 hrs after endotracheal extubation | VAS pain score 30min, 24 hrs and 48 hrs after extubation |
| Ccoughing on a four-point scale during anesthetic emergence | within 10 minutes after endotracheal extubation | Evaluate the severity of coughing within 10 minutes after extubation by a four-point scale |
| Heart rate | within 30 minutes after endotracheal extubation | Heart rate 1min, 5min, 10min, and 30min after extubation |
| mean arterial pressure | within 30 minutes after endotracheal extubation | Mean arterial pressure 1min, 5min, 10min, and 30min after extubation |
| Respiratory rate (RR) | within 30min after endotracheal extubation | Respiratory rate 1min, 5min, 10min, and 30min after extubation |
Countries
China
Contacts
Primary ContactSU Min, M.D.
Outcome results
None listed